Survodutide Research Peptide (BI456906 / GCGR/GLP-1R Dual Agonist)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses
Survodutide (BI 456906, CAS 2805997-46-8) is a synthetic 29 amino acid long-acting dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), developed by Boehringer Ingelheim in partnership with Zealand Pharma, supplied by Nextday Peptides in lyophilized format for laboratory and analytical research applications. Structurally distinct from oxyntomodulin-based dual agonists — Survodutide is a glucagon analog rather than an oxyntomodulin analog — incorporating a non-coded amino acid residue (Ac4c, 1-Aminocyclobutane-1-carboxylic acid) at position 2 for DPP-IV resistance, and a C18 fatty diacid moiety via a hydrophilic linker at lysine-24 for albumin-mediated half-life extension. In CHO-K1 cell assays it demonstrates EC50 values of 0.52 nM at GCGR and 0.33 nM at GLP-1R. For scientific research use only.
Compound Specifications
| Compound Name | Survodutide / BI 456906 |
| Classification | Glucagon-based dual GCGR/GLP-1R agonist — long-acting acylated peptide |
| Amino Acids | 29 |
| Receptor Targets | GCGR (EC50 0.52 nM) + GLP-1R (EC50 0.33 nM) in CHO-K1 cells |
| Structural Basis | Glucagon analog (not oxyntomodulin) — distinct from Mazdutide and Retatrutide |
| Position 2 Modification | Ac4c (1-Aminocyclobutane-1-carboxylic acid) — DPP-IV resistance |
| Acylation | C18 fatty diacid via hydrophilic linker at Lys-24 — albumin binding, half-life extension |
| CAS Number | 2805997-46-8 |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Purity | ≥99% (HPLC verified) |
| Storage | -20°C lyophilized; 2–8°C after reconstitution |
| Synonyms | BI 456906, BI456906, Survodutide peptide |
| Developer | Boehringer Ingelheim / Zealand Pharma |
Why Research Laboratories Select Survodutide
Survodutide is mechanistically unique among GLP-1R/GCGR dual agonists available for laboratory research — it is the only glucagon-based (not oxyntomodulin-based) dual agonist in clinical development, with a sub-nanomolar potency profile at both GCGR (EC50 0.52 nM) and GLP-1R (EC50 0.33 nM) and a non-coded amino acid at position 2 for DPP-IV resistance. This structural distinction from Mazdutide (oxyntomodulin-based) makes Survodutide an essential complementary reference compound for laboratories investigating glucagon scaffold versus oxyntomodulin scaffold pharmacology within the GCGR/GLP-1R dual agonist drug class.
- Glucagon-based scaffold — structurally distinct from oxyntomodulin-based dual agonists including Mazdutide
- Sub-nanomolar potency at both receptors — EC50 0.52 nM (GCGR) and 0.33 nM (GLP-1R) in CHO-K1 reference assays
- Ac4c at position 2 — non-coded amino acid providing DPP-IV resistance through steric mechanism
- C18 fatty diacid at Lys-24 — albumin-mediated half-life extension for sustained receptor engagement in experimental models
- Active Phase 3 clinical development — obesity and MASH (metabolic-associated steatohepatitis) programs by Boehringer Ingelheim
- Studied alongside Semaglutide as active comparator in Phase 2 trial — Blüher et al. (2023) Diabetologia
- Lyophilized format ensures stability and reproducibility across experimental runs
- Batch and lot identifiers on all labeling for full laboratory documentation compliance
Research Background
Survodutide was selected as clinical development candidate from 19 dual GCGR/GLP-1R agonists through a systematic biomarker-guided pharmacological profiling program described by Thomas et al. (2024) in Diabetes, Obesity and Metabolism. Zimmermann et al. (2022) published discovery and preclinical pharmacology data in Molecular Metabolism (BI 456906). Blüher et al. (2023) published Phase 2 dose-finding data in Diabetologia comparing Survodutide with placebo and open-label Semaglutide. A Phase 2 obesity dose-finding trial was published in a peer-reviewed journal. Phase 3 trials in obesity and MASH are ongoing as of 2025. Research-grade Survodutide supplied by Nextday Peptides is not equivalent to any approved pharmaceutical formulation. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.
Reference sources: Zimmermann et al. (2022) — Molecular Metabolism | Blüher et al. (2023) — Diabetologia (PMC)
Shipping & Fulfillment
- Ships from U.S. warehouses — Florida, North Carolina, and California
- Overnight and 2-day shipping available at checkout
- Same-day processing on orders placed before 3:30 PM ET
- Discreet packaging with full tracking provided
- Bulk research orders welcome — contact us for volume pricing
Storage & Handling
- Store lyophilized peptide at -20°C away from light and moisture
- After reconstitution store at 2–8°C and use within 7 days
- Avoid repeated freeze-thaw cycles to maintain peptide and acylation integrity
- Handle using appropriate laboratory safety protocols
- Keep containers sealed when not in use
Frequently Asked Questions
What is Survodutide?
Survodutide (BI 456906, CAS 2805997-46-8) is a synthetic 29 amino acid long-acting glucagon-based dual agonist of GCGR and GLP-1R, developed by Boehringer Ingelheim and Zealand Pharma. Unlike Mazdutide which is oxyntomodulin-based, Survodutide is built on a glucagon scaffold. It demonstrates EC50 values of 0.52 nM at GCGR and 0.33 nM at GLP-1R in CHO-K1 reference assays. Supplied strictly for scientific, analytical, and in-vitro laboratory research use only.
How does Survodutide differ from Mazdutide?
Both are dual GCGR/GLP-1R agonists but built on different structural scaffolds. Mazdutide (IBI362) is based on the oxyntomodulin backbone — an endogenous GLP-1R/GCGR dual agonist peptide. Survodutide (BI456906) is built on a glucagon backbone — a pure GCGR agonist scaffold that has been engineered to add GLP-1R activity. This fundamental scaffold difference results in different SAR profiles, potency distributions, and receptor binding kinetics that make them complementary research tools for comparative dual agonist pharmacology studies.
What is Ac4c at position 2 and why is it significant?
Ac4c (1-Aminocyclobutane-1-carboxylic acid) is a non-coded cyclic amino acid residue incorporated at position 2 of the Survodutide sequence. Position 2 is the primary site of dipeptidyl peptidase-4 (DPP-IV) enzymatic cleavage in glucagon-class peptides. The Ac4c residue provides steric protection at this position through its cyclobutane ring structure, dramatically enhancing resistance to DPP-IV degradation and extending the compound’s persistence in experimental systems.
How does Survodutide differ from Retatrutide?
Retatrutide (GLP-3R) is a triple GLP-1R/GIPR/GCGR agonist — adding GIP receptor activity to the GLP-1R/GCGR dual profile. Survodutide is a selective dual GCGR/GLP-1R agonist without significant GIPR activity. This makes Survodutide the reference tool for studying the isolated GLP-1R/GCGR dual axis in comparative experiments against single (Semaglutide), dual (Tirzepatide — GLP-1R/GIPR), and triple (Retatrutide) receptor profiles.
What purity is your Survodutide?
Every batch is independently verified to ≥99% HPLC purity. A Certificate of Analysis is available for each lot.
How fast does Nextday Peptides ship?
We ship from U.S. warehouses in Florida, North Carolina, and California. Overnight and 2-day shipping options are available. Orders placed before 3:30 PM ET are processed same day.
Are bulk orders available?
Yes. We accommodate bulk research orders. Contact us directly for volume pricing and availability.
Is this product approved for medical use?
No. Survodutide is not approved by the FDA or any regulatory authority for any indication. This product is for laboratory research use only and is not intended for diagnostic, therapeutic, or clinical applications.
What other compounds does Nextday Peptides carry?
We also carry Retatrutide GLP-3, Tirzepatide GLP-2T, Mazdutide IBI362, and Cagrilintide. View our full research compounds catalog.
For Research Use Only — Not for human or veterinary consumption • Not FDA approved for any indication • Supplied by Nextday Peptides for controlled in-vitro laboratory research use only
